Key result
Editorial outlines how to interpret current evidence on revascularization in ischaemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Editorial advises caution applying revascularization evidence to ischaemic cardiomyopathy; leaves open optimal strategy pending further trials.
Journal Article Revascularization in ischaemic cardiomyopathy: how to interpret current evidence Get access Bernard J Gersh, Bernard J Gersh Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA Corresponding author. Tel: +1 507 284 4139, Fax: +1 507 266 0103, Email: gersh.bernard@mayo.edu https://orcid.org/0000-0001-5605-900X Search for other works by this author on: Oxford Academic PubMed Google Scholar David De Mets David De Mets Department of Biostatistics & Medical Informatics, School of Medicine & Public Health, University of Wisconsin–Madison,Madison, WI, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, Volume 44, Issue 5, 1 February 2023, Pages 365–367, https://doi.org/10.1093/eurheartj/ehac794 Published: 25 November 2022
No takes yet. Share an insight, caveat, or question.
Gersh et al. (2022) conducted an editorial in ischaemic cardiomyopathy. Revascularization was evaluated. This article is an editorial discussing how to interpret current evidence on revascularization in ischaemic cardiomyopathy, with no primary data reported.
Synapse has enriched 10 related papers. Consider them for comparative context: